A huge percentage of the increase in health spending is caused by very expensive drugs administered in a provider’s office.
A National Bureau of Economic Research paper confirms earlier research on the effect of drug rebates on net prices to drug makers.
MedPAC’s annual report to Congress includes examination of the effects of hospital consolidation and abuses of the 340B program.
A JAMA Article examines what it costs to develop a new drug.
A study in JAMA reveals once again the avaricious pricing behavior of drug companies.
A study in JAMA discusses the profitability of large drug companies.
Giving doctors more information about a patient’s adherence to prescriptions and access to pharmacist help did not improve adherence to medication regimens.
Drug manufacturer payments to doctors appear to have modest effects on prescribing behavior.
Express Scripts gives us its version of 2019 prescription drug spending and utilization trends.
A study in JAMA Internal Medicine describes trends in drug manufacturer detailing of physicians.
A paper from EBRI discusses differences in cost for the same cancer medication in different sites of service.
A Statistical Brief from AHRQ examines certain trends in costs of retail drugs.
A new study relating to hospitals participation in the 340B program finds that they are making excellent profits, which was not the intention.
The Government Accounting Office releases a report on the role of pharmacy benefit managers in Medicare Part D.